Cure My Disease

Don't miss your cure!

 Log in / Sign up

5,500 patients to test new heart valve devices in massive safety study

NCT ID NCT07605624

Not yet recruiting Knowledge-focused Sponsor: Beijing Anzhen Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will follow 5,500 people in China who receive new heart valve devices (replacement or repair) for conditions like aortic stenosis or mitral regurgitation. Researchers will track safety issues such as stroke, bleeding, and device function over time. The goal is to see how well these devices work in everyday medical practice, not just in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
heart valve devices (replacement or repair implants)
What this could lead to
If successful, this study will provide real-world evidence on the safety and effectiveness of these devices, helping doctors choose the best treatment for valve disease.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be affected by differences in patient care and may not apply outside China.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC REGURGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve insufficiency aortic valve stenosis mitral valve insufficiency tricuspid valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC REGURGITATION AORTIC STENOSIS MITRAL REGURGITATION TRICUSPID REGURGITATION

Contacts and locations

Locations

  • Beijing Anzhen Hospital

    Beijing, Beijing Municipality, 100029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.